NCT06755489View on ClinicalTrials.gov

Quality of Life in Diarrhea-predominant Irritable Bowel Syndrome Taking GABA

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 17, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2025

Conditions
Diarrhoea Predominant Irritable Bowel Syndrome
Interventions
OTHER

Placebo

530 mg tablets containing microcrystalline cellulose, rice bran, bitter cocoa powder table 530 mg. 1 tablet three times a day

OTHER

GABA

530 mg tablets containing Gamma-aminobutyric acid (GABA) and different bulking agent as microcrystalline cellulose, calcium carbonate, lemon balm d.e. Leaves (melissa officinalis l. - maltodextrin) tit. 2% in rosmarinic acid, anti-caking agents: silicon dioxide, vegetable magnesium stearate. 1 tablet three times a day

Trial Locations (2)

56124

RECRUITING

Azienda Ospedaliero Universitaria Pisana, Pisa

56126

RECRUITING

University of Pisa, Pisa

All Listed Sponsors
collaborator

Azienda Ospedaliero-Universitaria Pisana (AOUP)

UNKNOWN

lead

University of Pisa

OTHER